Literature DB >> 18946659

Increased circulating regulatory T cells (CD4(+)CD25 (+)CD127 (-)) contribute to lymphocyte anergy in septic shock patients.

Fabienne Venet1, Chun-Shiang Chung, Hakim Kherouf, Anne Geeraert, Chistophe Malcus, Françoise Poitevin, Julien Bohé, Alain Lepape, Alfred Ayala, Guillaume Monneret.   

Abstract

PURPOSE: Sepsis syndrome represents the leading cause of death in intensive care unit. Patients present features consistent with a decline in immune responsiveness potentially contributing to mortality. We investigated whether CD4(+)CD25(+) regulatory T cells (Treg) participate in the induction of lymphocyte anergy after sepsis.
METHOD: Observational study in septic shock patients and experimental study in mice.
RESULTS: We took advantage of the recently described flow cytometric gating strategy using the measurement of CD25 and CD127 expressions for monitoring Treg (CD4(+)CD25(+)CD127(-)Foxp3(+)). In patients the increased circulating Treg percentage significantly correlated with a decreased lympho-proliferative response. In a murine model of sepsis mimicking these observations, the ex vivo downregulation of Foxp3 expression using siRNA was associated with a restoration of this response.
CONCLUSION: The relative increase in circulating Treg might play a role in lymphocyte anergy described after septic shock and represent a standardizable surrogate marker of declining proliferative capacity after sepsis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18946659      PMCID: PMC2789433          DOI: 10.1007/s00134-008-1337-8

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  46 in total

1.  Increased natural CD4+CD25+ regulatory T cells and their suppressor activity do not contribute to mortality in murine polymicrobial sepsis.

Authors:  Philip O Scumpia; Matthew J Delano; Kindra M Kelly; Kerri A O'Malley; Philip A Efron; Priscilla F McAuliffe; Todd Brusko; Ricardo Ungaro; Tolga Barker; James L Wynn; Mark A Atkinson; Westley H Reeves; Michael J Clare Salzler; Lyle L Moldawer
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

2.  Lipopolysaccharide-activated CD4+CD25+ T regulatory cells inhibit neutrophil function and promote their apoptosis and death.

Authors:  Przemyslaw Lewkowicz; Natalia Lewkowicz; Andrzej Sasiak; Henryk Tchórzewski
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

Review 3.  Cell-surface IL-7 receptor expression facilitates the purification of FOXP3(+) regulatory T cells.

Authors:  Alison H Banham
Journal:  Trends Immunol       Date:  2006-10-12       Impact factor: 16.687

4.  Human CD4+CD25+ regulatory T lymphocytes inhibit lipopolysaccharide-induced monocyte survival through a Fas/Fas ligand-dependent mechanism.

Authors:  Fabienne Venet; Alexandre Pachot; Anne-Lise Debard; Julien Bohe; Jacques Bienvenu; Alain Lepape; William S Powell; Guillaume Monneret
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

5.  Increased CD4+ CD25+ T regulatory cell activity in trauma patients depresses protective Th1 immunity.

Authors:  Malcolm P MacConmara; Adrian A Maung; Satoshi Fujimi; Ann M McKenna; Adam Delisle; Peter H Lapchak; Selwyn Rogers; James A Lederer; John A Mannick
Journal:  Ann Surg       Date:  2006-10       Impact factor: 12.969

Review 6.  Human regulatory T cells and their role in autoimmune disease.

Authors:  Clare Baecher-Allan; David A Hafler
Journal:  Immunol Rev       Date:  2006-08       Impact factor: 12.988

Review 7.  Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease.

Authors:  Shimon Sakaguchi; Masahiro Ono; Ruka Setoguchi; Haruhiko Yagi; Shohei Hori; Zoltan Fehervari; Jun Shimizu; Takeshi Takahashi; Takashi Nomura
Journal:  Immunol Rev       Date:  2006-08       Impact factor: 12.988

Review 8.  A mini meta-analysis of studies on CD4+CD25+ T cells in human type 1 diabetes: report of the Immunology of Diabetes Society T Cell Workshop.

Authors:  Timothy I M Tree; Bart O Roep; Mark Peakman
Journal:  Ann N Y Acad Sci       Date:  2006-10       Impact factor: 5.691

9.  Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells.

Authors:  Nabila Seddiki; Brigitte Santner-Nanan; Jeff Martinson; John Zaunders; Sarah Sasson; Alan Landay; Michael Solomon; Warwick Selby; Stephen I Alexander; Ralph Nanan; Anthony Kelleher; Barbara Fazekas de St Groth
Journal:  J Exp Med       Date:  2006-07-03       Impact factor: 14.307

10.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells.

Authors:  Weihong Liu; Amy L Putnam; Zhou Xu-Yu; Gregory L Szot; Michael R Lee; Shirley Zhu; Peter A Gottlieb; Philipp Kapranov; Thomas R Gingeras; Barbara Fazekas de St Groth; Carol Clayberger; David M Soper; Steven F Ziegler; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2006-07-03       Impact factor: 14.307

View more
  119 in total

1.  Melatonin augments apoptotic adipose-derived mesenchymal stem cell treatment against sepsis-induced acute lung injury.

Authors:  Hong-Hwa Chen; Chia-Lo Chang; Kun-Chen Lin; Pei-Hsun Sung; Han-Tan Chai; Yen-Yi Zhen; Yi-Ching Chen; Ying-Chung Wu; Steve Leu; Tzu-Hsien Tsai; Chih-Hung Chen; Hsueh-Wen Chang; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

2.  Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination.

Authors:  Matteo Vergati; Vittore Cereda; Ravi A Madan; James L Gulley; Ngar-Yee Huen; Connie J Rogers; Kenneth W Hance; Philip M Arlen; Jeffrey Schlom; Kwong Y Tsang
Journal:  Cancer Immunol Immunother       Date:  2010-10-26       Impact factor: 6.968

Review 3.  Epigenetic regulation of immune cell functions during post-septic immunosuppression.

Authors:  William F Carson; Karen A Cavassani; Yali Dou; Steven L Kunkel
Journal:  Epigenetics       Date:  2011-03-01       Impact factor: 4.528

4.  Mesenchymal stem cells: another anti-inflammatory treatment for sepsis?

Authors:  Guillaume Monneret
Journal:  Nat Med       Date:  2009-06       Impact factor: 53.440

5.  Dose-dependent effect of anti-CTLA-4 on survival in sepsis.

Authors:  Shigeaki Inoue; Lulong Bo; Jinjun Bian; Jacqueline Unsinger; Katherine Chang; Richard S Hotchkiss
Journal:  Shock       Date:  2011-07       Impact factor: 3.454

Review 6.  Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach.

Authors:  Richard S Hotchkiss; Guillaume Monneret; Didier Payen
Journal:  Lancet Infect Dis       Date:  2013-03       Impact factor: 25.071

7.  A grim picture, indeed.

Authors:  J Jason Hoth
Journal:  Crit Care Med       Date:  2013-03       Impact factor: 7.598

8.  Cold-inducible RNA-binding protein activates splenic T cells during sepsis in a TLR4-dependent manner.

Authors:  Alexandra C Bolognese; Archna Sharma; Weng-Lang Yang; Jeffrey Nicastro; Gene F Coppa; Ping Wang
Journal:  Cell Mol Immunol       Date:  2016-08-29       Impact factor: 11.530

9.  Year in review in Intensive Care Medicine 2009: II. Neurology, cardiovascular, experimental, pharmacology and sedation, communication and teaching.

Authors:  Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang
Journal:  Intensive Care Med       Date:  2010-01-28       Impact factor: 17.440

10.  Association between regulatory T cell activity and sepsis and outcome of severely burned patients: a prospective, observational study.

Authors:  Li-Feng Huang; Yong-Ming Yao; Ning Dong; Yan Yu; Li-Xin He; Zhi-Yong Sheng
Journal:  Crit Care       Date:  2010-01-11       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.